Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3

Conditions

Multiple Myeloma 6Neoplasm Metastasis 4Carcinoma 4Breast Neoplasms 4Neoplasms 3Melanoma 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Glioma 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Unspecified Childhood Solid Tumor, Protocol Specific 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Rhabdoid Tumor 1Recurrence 1Ras-mutated Metastatic Colorectal Cancer 1Prostatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Medulloblastoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Glioblastoma 1Fibrosarcoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × reolysin × Clear all
NCT01274624 2018-12-19

Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

Oncolytics Biotech

Phase 1 Completed
36 enrolled
Tumor-Agnostic

Neoplasms

NCT02620423 2018-09-13

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Oncolytics Biotech

Phase 1 Completed
11 enrolled
Tumor-Agnostic

Neoplasms

NCT02723838 2017-03-07

Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

Oncolytics Biotech

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡